Pain Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of drugs for use in pain management, primarily in the area of opioid painkillers in the United States. Its Phase III clinical trial products include Remoxy, which is an anti-abuse version of long-acting oxycodone; and Oxytrex, which is an opioid painkiller for the treatment of chronic pain. The company has a strategic alliance with King Pharmaceuticals, Inc. for the development and commercialization of Remoxy and other abuse-resistant opioid painkillers. Pain Therapeutics was founded in 1998 and is based in South San Francisco, California.